

## Prostatype Genomics AB enters into pre-subscription and top-down underwriting commitments corresponding to 37.2 percent in ongoing warrant exercise

**NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.**

**Prostatype Genomics AB ("Prostatype Genomics" or "the Company") has entered into agreements regarding pre-subscription commitments and so-called top-down underwriting corresponding to a total of approximately 37.2 percent (SEK 4.4 million) of outstanding warrants of series T05 ("T05"). Of these, approximately 22.2 percent (SEK 2.6 million) are pre-subscription commitments from board members and an existing warrant holder. In addition, there are top-down underwriting commitments corresponding to approximately 15.0 percent (SEK 1.8 million) from two external guarantors. The underwriting will take effect if not all T05 are exercised. The exercise period for T05 began today, 3 September 2025, and runs until September 17, 2025. The last trading day for T05 is September 15, 2025.**

In May/June 2025, Prostatype Genomics carried out a rights issue which brought the Company approximately SEK 27.3 million before issue costs. Through the rights issue and a directed issue to the underwriters in the rights issue, 22,623,789 T05 were issued. Each T05 entitles the holder to subscribe for one (1) new share in Prostatype Genomics during the exercise period, which runs 3-17 September 2025. The exercise price for T05 is SEK 0.52 per share. In the event of full utilization of T05, approximately SEK 11.8 million will be added to the Company before issue costs.

Upon full utilization of T05, the number of shares in Prostatype Genomics will increase by 22,623,789 shares to a total of 59,624,054 shares and the share capital will increase by SEK 2,262,378.90 to SEK 5,962,405.40. The dilution at full utilization amounts to approximately 38 percent of the capital and votes.

Complete terms and instructions for T05 are available on the Company's website ([www.prostatypegenomics.com](http://www.prostatypegenomics.com)). A teaser containing summary information about T05 is available on Prostatype Genomics' ([www.prostatypegenomics.com](http://www.prostatypegenomics.com)) website as well as on Nordic Issuing AB's ([www.nordic-issuing.se](http://www.nordic-issuing.se)) website.

**Pre-subscription- and top-down underwriting commitments**

The Company has received pre-subscription commitments corresponding to approximately 22.2 percent (SEK 2.6 million) of T05 from board members and a major existing warrant holder. All of these have undertaken to exercise their T05 holdings in full.

In addition to the pre-subscription commitments, the Company has entered into agreements with two external underwriters (top-down) corresponding to approximately 15.0 percent (SEK 1.8 million) of T05. The underwriters will receive compensation of either 15.0 percent in cash or 18.0 percent in shares, on the same terms as T05.

The underwriting commitments are not secured by bank guarantees, pledges, or similar. They will be activated if the subscription of shares based on T05 is less than 100 percent. Subscription within the framework of the underwriting commitments will take place through a directed issue, resolved by the Board of Directors with support by the authorization of the Annual General Meeting on May 15, 2025.

**Advisors**

Navia Corporate Finance AB and Gemstone Capital ApS are financial advisors in connection with the transaction. Advokatfirman Lindahl is the legal advisor. Nordic Issuing AB is the issuing agent.

**For more information about the transaction, please contact:**

Navia Corporate Finance AB

E-mail: [info@naviacf.se](mailto:info@naviacf.se)

Website: [www.naviacorporatefinance.com](http://www.naviacorporatefinance.com)

or

Gemstone Capital ApS

E-mail: [info@gemstonecapital.com](mailto:info@gemstonecapital.com)

Website: [www.gemstonecapital.com](http://www.gemstonecapital.com)

**For more information about the Company, please contact:**

Fredrik Rickman, CEO Prostatype Genomics AB

Telephone: +46 (0)73 049 77 01

E-mail: [fredrik.rickman@prostatypegenomics.com](mailto:fredrik.rickman@prostatypegenomics.com)

**Certified Adviser**

Tapper Partners AB

Telephone: +46 (0)70 44 010 98

E-mail: [ca@tapperpartners.se](mailto:ca@tapperpartners.se)

**About Prostatype Genomics**

Prostatype® is a genetic test available to patients and treating urologists as a complementary decision-making tool when considering treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

**Important information**

The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in Prostatype Genomics. No action has been taken, and no action will be taken to permit an offer to the public in any jurisdictions other than Sweden. The invitation to interested persons to subscribe for shares in Prostatype Genomics takes place solely through the prospectus that Prostatype Genomics has published in May 2025.

The information contained in this press release may not be disclosed, published or distributed, directly or indirectly, within or to the United States, Belarus, Russia, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction where such action would be illegal, subject to legal restrictions or require measures other than those that follow from Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation. No shares or other securities of Prostatype Genomics have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933 from time to time ("Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and pursuant to the securities laws of the relevant state or other jurisdiction in the United States. This communication is distributed to and directed solely to persons in the United Kingdom who are (i) professional investors falling within the scope of Article 19(5) of the U.K. from time to time in force; Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("the Order") or (ii) high net worth subjects and other persons to whom this notice may lawfully be addressed, who are subject to Article 49(2)(a)-(d) in the Order (all such persons are collectively referred to as "Relevant Persons"). Persons who are not Relevant Persons may not act on or rely on the information in this communication. An investment or investment measure referred to in this communication is only possible for Relevant Persons and will only be completed with Relevant Persons. Persons who disseminate this communication must themselves ensure that such dissemination is permitted.

**Forward-looking Statements**

This press release contains forward-looking statements that refer to the Company's intentions, assessments or expectations regarding the Company's future results, financial position, liquidity, development, prospects, expected growth, strategies and opportunities as well as the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and can be identified by the inclusion of expressions such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "assumes", "should" "could" and, in each case, negations thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will occur or that they are accurate. As these assumptions are based on assumptions or estimates and are subject to risks and uncertainties, the actual result or outcome may, for many different reasons, differ materially from what appears in the forward-looking statements.

Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in this press release through the forward-looking statements. The Company does not warrant that the assumptions underlying the forward-looking statements in this press release are correct and any reader of the press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements expressed or implied herein are provided only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertakes to revise, update, confirm or publicly announce any revision of any forward-looking statement to reflect events occurring or circumstances occurring with respect to the contents of this press release, except as required by law or Nasdaq First North Growth Markets' regulations for issuers.

*This information is information that Prostatype Genomics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-09-03 20:55 CEST.*